SG11201708846XA - Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants - Google Patents
Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvantsInfo
- Publication number
- SG11201708846XA SG11201708846XA SG11201708846XA SG11201708846XA SG11201708846XA SG 11201708846X A SG11201708846X A SG 11201708846XA SG 11201708846X A SG11201708846X A SG 11201708846XA SG 11201708846X A SG11201708846X A SG 11201708846XA SG 11201708846X A SG11201708846X A SG 11201708846XA
- Authority
- SG
- Singapore
- Prior art keywords
- immunotherapies
- methods
- small molecule
- novel compositions
- integrin receptor
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by a specific adjuvant, e.g. cytokines or CpG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154554P | 2015-04-29 | 2015-04-29 | |
| US15/140,711 US10342866B2 (en) | 2015-04-29 | 2016-04-28 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
| PCT/US2016/029683 WO2016176400A2 (en) | 2015-04-29 | 2016-04-28 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708846XA true SG11201708846XA (en) | 2017-11-29 |
Family
ID=57198770
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911607YA SG10201911607YA (en) | 2015-04-29 | 2016-04-28 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
| SG11201708846XA SG11201708846XA (en) | 2015-04-29 | 2016-04-28 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911607YA SG10201911607YA (en) | 2015-04-29 | 2016-04-28 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US10342866B2 (en) |
| JP (2) | JP2018514562A (en) |
| KR (3) | KR20240052079A (en) |
| CN (1) | CN107820429B (en) |
| AU (1) | AU2016254034B2 (en) |
| CA (1) | CA2984316A1 (en) |
| IL (1) | IL255297B (en) |
| MX (1) | MX2017013859A (en) |
| SG (2) | SG10201911607YA (en) |
| WO (1) | WO2016176400A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311619B2 (en) * | 2016-04-28 | 2022-04-26 | 7 Hills Pharma Inc. and Texas Heart Institute | Integrin activator vaccine compositions |
| CN107820429B (en) * | 2015-04-29 | 2022-08-16 | 7山药物有限责任公司 | Novel compositions and methods for immunotherapy comprising small molecule integrin receptor-ligand agonist adjuvants |
| WO2018112364A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating melanoma |
| WO2018112360A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating cancer |
| EP4013446A1 (en) * | 2019-08-16 | 2022-06-22 | The Regents of the University of California | Combined cancer therapy involving chemical activation of integrins and targeted cell immunotherapy |
| US20220118086A1 (en) * | 2020-09-10 | 2022-04-21 | 7 Hills Pharma LLC | Integrin agonists or activating compounds and methods for making and using same |
| KR20240046893A (en) * | 2021-08-10 | 2024-04-11 | 텍사스 하트 인스티튜트 | Aminoaryl-integrin agonist compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003053966A2 (en) * | 2001-12-20 | 2003-07-03 | Laboratorios S.A.L.V.A.T., S.A. | 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists |
| AU2005249566B2 (en) * | 2004-06-04 | 2010-11-11 | Genentech, Inc. | Method for treating multiple sclerosis |
| TW200744659A (en) * | 2005-07-26 | 2007-12-16 | Shiseido Co Ltd | Preparation for preventing and ameliorating wrinkle |
| EP2160408A1 (en) * | 2007-06-22 | 2010-03-10 | Bayer Schering Pharma Aktiengesellschaft | Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease |
| US10369204B2 (en) * | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| JP5624130B2 (en) * | 2009-06-12 | 2014-11-12 | アクテリオンファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Oxazole and thiazole derivatives as ALX receptor agonists |
| NZ746603A (en) * | 2010-11-16 | 2020-05-29 | Texas Heart Inst | Agonists that enhance binding of integrin-expressing cells to integrin receptors |
| EP3104867B1 (en) | 2014-02-12 | 2022-01-19 | 7 Hills Pharma LLC | Compositions and methods to improve the homing and grafting of hematopoetic stem cells |
| JP2017521435A (en) | 2014-07-01 | 2017-08-03 | セヴン ヒルズ インタレスツ リミテッド ライアビリティ カンパニー | Compositions and methods for improving adoptive cell therapy |
| CN107820429B (en) * | 2015-04-29 | 2022-08-16 | 7山药物有限责任公司 | Novel compositions and methods for immunotherapy comprising small molecule integrin receptor-ligand agonist adjuvants |
-
2016
- 2016-04-28 CN CN201680036891.3A patent/CN107820429B/en active Active
- 2016-04-28 SG SG10201911607YA patent/SG10201911607YA/en unknown
- 2016-04-28 AU AU2016254034A patent/AU2016254034B2/en active Active
- 2016-04-28 JP JP2017556837A patent/JP2018514562A/en active Pending
- 2016-04-28 MX MX2017013859A patent/MX2017013859A/en unknown
- 2016-04-28 WO PCT/US2016/029683 patent/WO2016176400A2/en active Application Filing
- 2016-04-28 KR KR1020247011632A patent/KR20240052079A/en active Application Filing
- 2016-04-28 SG SG11201708846XA patent/SG11201708846XA/en unknown
- 2016-04-28 KR KR1020177034574A patent/KR20170136651A/en not_active IP Right Cessation
- 2016-04-28 US US15/140,711 patent/US10342866B2/en active Active
- 2016-04-28 KR KR1020247011631A patent/KR20240052078A/en active Application Filing
- 2016-04-28 CA CA2984316A patent/CA2984316A1/en active Pending
-
2017
- 2017-10-27 IL IL255297A patent/IL255297B/en unknown
-
2019
- 2019-04-25 US US16/394,277 patent/US10716849B2/en active Active
- 2019-04-25 US US16/394,270 patent/US10709780B2/en active Active
- 2019-07-19 US US16/516,907 patent/US10709781B2/en active Active
-
2021
- 2021-05-06 JP JP2021078488A patent/JP7244570B2/en active Active
- 2021-06-29 US US17/362,512 patent/US20220001009A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL255297A0 (en) | 2017-12-31 |
| SG10201911607YA (en) | 2020-01-30 |
| IL255297B (en) | 2021-10-31 |
| KR20240052078A (en) | 2024-04-22 |
| JP2021121602A (en) | 2021-08-26 |
| CN107820429A (en) | 2018-03-20 |
| AU2016254034B2 (en) | 2021-11-04 |
| US20160339098A1 (en) | 2016-11-24 |
| CA2984316A1 (en) | 2016-11-03 |
| US10709781B2 (en) | 2020-07-14 |
| CN107820429B (en) | 2022-08-16 |
| CN107820429A8 (en) | 2018-06-01 |
| US20220001009A1 (en) | 2022-01-06 |
| US20190343952A1 (en) | 2019-11-14 |
| US10716849B2 (en) | 2020-07-21 |
| US20190351052A1 (en) | 2019-11-21 |
| JP7244570B2 (en) | 2023-03-22 |
| KR20240052079A (en) | 2024-04-22 |
| WO2016176400A3 (en) | 2016-12-08 |
| JP2018514562A (en) | 2018-06-07 |
| US20200054743A1 (en) | 2020-02-20 |
| US10342866B2 (en) | 2019-07-09 |
| US10709780B2 (en) | 2020-07-14 |
| WO2016176400A2 (en) | 2016-11-03 |
| MX2017013859A (en) | 2018-07-06 |
| AU2016254034A1 (en) | 2017-12-14 |
| KR20170136651A (en) | 2017-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1257751A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| IL248347B (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| IL248311A0 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| HK1253306A1 (en) | Anti-ntb-a antibodies and related compositions and methods | |
| IL255297A0 (en) | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | |
| HK1245302A1 (en) | Carrier molecule compositions and related methods | |
| HUE052714T2 (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
| PL3217978T3 (en) | Compositions comprising substituted benzofuroquinolizine and alpha2-adrenergic agonists | |
| EP3160961A4 (en) | Small molecule agonists of neurotensin receptor 1 | |
| PL3209828T3 (en) | N-halamine containing fibrous compositions and uses thereof | |
| PT3239177T (en) | Novel egfrviii antibody and composition comprising same | |
| EP3288585A4 (en) | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | |
| EP3102557A4 (en) | Improved compositions and methods comprising resveratrol | |
| GB201621528D0 (en) | Use of trpv1 agonist | |
| IL247872A0 (en) | Stat5 inhibitors and use thereof | |
| PT3247719T (en) | Met receptor agonist proteins |